VJET Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About VJET Interactive Breakdown Better Bets vs. VJET Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Flyte Aviation (VJET)

    Market Price (10/7/2026): $0.9119 | Market Cap: $0.3 MilSector: Health Care | Industry: Life Sciences Tools & Services

    Flyte Aviation (VJET)

    Market Price (10/7/2026): $0.9119
    Market Cap: $0.3 Mil
    Sector: Health Care
    Industry: Life Sciences Tools & Services

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Strong revenue growth
    Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 219%

    Megatrend and thematic drivers
    Megatrends include Advanced Aviation & Space. Themes include Advanced Air Mobility.

    Trading close to highs
    Dist 52W High is 0.0%

    Weak multi-year price returns
    3Y Excs Rtn is -84%

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -12 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -635%

    Stock price has recently run up significantly
    6M Rtn6 month market price return is 1029900%, 12M Rtn12 month market price return is 1029900%

    Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25%

    Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -488%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -501%

    High stock price volatility
    Vol 12M is 1029900%

    Key risks
    VJET key risks include [1] substantial doubt about its ability to continue as a going concern due to significant and continued losses, Show more.

    0 Strong revenue growth
    Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 219%
    1 Megatrend and thematic drivers
    Megatrends include Advanced Aviation & Space. Themes include Advanced Air Mobility.
    2 Trading close to highs
    Dist 52W High is 0.0%
    3 Weak multi-year price returns
    3Y Excs Rtn is -84%
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -12 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -635%
    5 Stock price has recently run up significantly
    6M Rtn6 month market price return is 1029900%, 12M Rtn12 month market price return is 1029900%
    6 Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25%
    7 Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -488%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -501%
    8 High stock price volatility
    Vol 12M is 1029900%
    9 Key risks
    VJET key risks include [1] substantial doubt about its ability to continue as a going concern due to significant and continued losses, Show more.

    Valuation & Metrics

    null
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Registered Accounts10000+8202026Link
    Planned Fleet Size10 Vision Jets and 3 Pilatus aircraft12312026Link
    Airports Served1748202026Link
    States with Users198202026Link

    Price Chart

    Upcoming
    10/05/2026Stock SplitRatio: 1-for-10
    11/12/2026Earnings ReleaseRev: $2.0 Mil (E)
    EPS: $-13.30 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 10/6/2026

    Flyte Aviation (VJET) stock has gained about 1029900% since 6/30/2026 because of the following key factors:

    1. Strategic Rebranding and Pivot into Private Aviation: Flyte Aviation, formerly Catheter Precision, Inc., completed a significant rebranding and strategic pivot on October 5, 2026, changing its NYSE American ticker from VTAK to VJET. This involved shifting its core business from medical technologies to the private, regional jet aviation and technology sector. The company is now focused on disrupting the U.S. private jet charter market, estimated at $11.6 billion in 2026, with an AI-enabled booking platform, a move that likely generated substantial investor interest in a high-growth, technology-driven sector.

    2. 1-for-10 Reverse Stock Split: Effective October 5, 2026, the company executed a 1-for-10 reverse stock split. This corporate action dramatically increased the per-share price, significantly contributing to the reported percentage gain in the stock's value, particularly when measured from a potentially very low pre-split price. For instance, a pre-split closing price of $0.1520 on October 1, 2026, would translate to approximately $1.52 after the split.

    Show more
    Updated on 10/6/2026

    Flyte Aviation (VJET) stock has gained about 1029900% since 6/30/2026 because of the following key factors:

    1. Strategic Rebranding and Pivot into Private Aviation: Flyte Aviation, formerly Catheter Precision, Inc., completed a significant rebranding and strategic pivot on October 5, 2026, changing its NYSE American ticker from VTAK to VJET. This involved shifting its core business from medical technologies to the private, regional jet aviation and technology sector. The company is now focused on disrupting the U.S. private jet charter market, estimated at $11.6 billion in 2026, with an AI-enabled booking platform, a move that likely generated substantial investor interest in a high-growth, technology-driven sector.

    2. 1-for-10 Reverse Stock Split: Effective October 5, 2026, the company executed a 1-for-10 reverse stock split. This corporate action dramatically increased the per-share price, significantly contributing to the reported percentage gain in the stock's value, particularly when measured from a potentially very low pre-split price. For instance, a pre-split closing price of $0.1520 on October 1, 2026, would translate to approximately $1.52 after the split.

    3. Significant Capital Infusion: The company received $8.793 million in funding through a private placement that closed on July 15, 2026. This substantial capital injection likely bolstered investor confidence in the company's ability to fund its operations and strategic initiatives, including its new focus on aviation technology.

    4. Positive Intellectual Property Developments: In early fiscal Q3 2026, on July 7, 2026, the company (then Catheter Precision, Inc.) announced it secured two new patents for heart failure and cardiac mapping technologies. These patents were noted to be related to systems already in early clinical trials, with initial results described as promising, indicating valuable intellectual property in its original medical device segment.

    5. Improved Financial Performance Leading to Strategic Shift: In fiscal Q2 2026 (ended June 30, 2026), the company reported a narrowed net loss of US$1.46 per share, an improvement from a US$7.17 loss per share in fiscal Q2 2025. Additionally, revenue in fiscal Q2 2026 saw a substantial increase of 380.66% year-over-year, reaching $1.02 million. This demonstrated a positive trend in its financial performance prior to the major strategic transformation.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The 1029900.0% change in VJET stock from 6/30/2026 to 10/6/2026 was primarily driven by a 752353.3% change in the company's P/S Multiple.
    (LTM values as of)630202610062026Change
    Stock Price ($)0.001.031029900.0%
    Change Contribution By: 
    Total Revenues ($ Mil)1272.8%
    P/S Multiple0.00.1752353.3%
    Shares Outstanding (Mil)00-20.8%
    Cumulative Contribution1029900.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2026 to 10/6/2026
    ReturnCorrelation
    VJET1029900.0% 
    Market (SPY)4.3%�
    Sector (XLV)5.3%�

    Fundamental Drivers

    The 1029900.0% change in VJET stock from 3/31/2026 to 10/6/2026 was primarily driven by a 700941.1% change in the company's P/S Multiple.
    (LTM values as of)331202610062026Change
    Stock Price ($)0.001.031029900.0%
    Change Contribution By: 
    Total Revenues ($ Mil)12133.8%
    P/S Multiple0.00.1700941.1%
    Shares Outstanding (Mil)00-37.2%
    Cumulative Contribution1029900.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    3/31/2026 to 10/6/2026
    ReturnCorrelation
    VJET1029900.0% 
    Market (SPY)20.1%�
    Sector (XLV)14.5%�

    Fundamental Drivers

    The 1029900.0% change in VJET stock from 9/30/2025 to 10/6/2026 was primarily driven by a 1272315.2% change in the company's P/S Multiple.
    (LTM values as of)930202510062026Change
    Stock Price ($)0.001.031029900.0%
    Change Contribution By: 
    Total Revenues ($ Mil)12219.2%
    P/S Multiple0.00.11272315.2%
    Shares Outstanding (Mil)00-74.6%
    Cumulative Contribution1029900.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2025 to 10/6/2026
    ReturnCorrelation
    VJET1029900.0% 
    Market (SPY)17.9%14.1%
    Sector (XLV)21.6%-8.4%

    Fundamental Drivers

    The -1.9% change in VJET stock from 9/30/2023 to 10/6/2026 was primarily driven by a -99.5% change in the company's Shares Outstanding (Mil).
    (LTM values as of)930202310062026Change
    Stock Price ($)1.051.03-1.9%
    Change Contribution By: 
    Total Revenues ($ Mil)022027.8%
    P/S Multiple0.00.1789.7%
    Shares Outstanding (Mil)00-99.5%
    Cumulative Contribution-1.9%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2023 to 10/6/2026
    ReturnCorrelation
    VJET-1.9% 
    Market (SPY)88.5%�
    Sector (XLV)35.9%�

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    VJET Return-40%-61%-45%-97%-100%0%-100%
    Peers Return-27%-38%-60%-61%-45%-74%-99%
    S&P 500 Return27%-19%24%23%16%14%107%

    Monthly Win Rates [3]
    VJET Win Rate33%33%33%33%18%0% 
    Peers Win Rate38%38%42%31%31%32% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    VJET Max Drawdown-84%-72%-62%-100%-100%0% 
    Peers Max Drawdown-64%-40%-74%-87%-76%-89% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: UP, FLYX, SRFM, JTAI.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 10/6/2026 (YTD)

    How Low Can It Go

    EventVJETS&P 500
    2025 US Tariff Shock
      % Loss-100.0%-18.8%
      % Gain to Breakeven∞%23.1%
      Time to Breakeven509 days79 days
    2020 COVID-19 Crash
      % Loss-61.9%-33.7%
      % Gain to Breakeven162.4%50.9%
      Time to Breakeven80 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-60.6%-19.2%
      % Gain to Breakeven153.7%23.8%
      Time to Breakeven772 days105 days
    2016-2017 Trump Reflation Bond Selloff
      % Loss-43.8%-3.7%
      % Gain to Breakeven78.1%3.9%
      Time to Breakeven46 days6 days
    2015-2016 China Devaluation / Global Growth Scare
      % Loss-44.8%-12.2%
      % Gain to Breakeven81.3%13.9%
      Time to Breakeven1847 days62 days

    Compare to UP, FLYX, SRFM, JTAI

    In The Past

    Flyte Aviation's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventVJETS&P 500
    2025 US Tariff Shock
      % Loss-100.0%-18.8%
      % Gain to Breakeven∞%23.1%
      Time to Breakeven509 days79 days
    2020 COVID-19 Crash
      % Loss-61.9%-33.7%
      % Gain to Breakeven162.4%50.9%
      Time to Breakeven80 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-60.6%-19.2%
      % Gain to Breakeven153.7%23.8%
      Time to Breakeven772 days105 days
    2016-2017 Trump Reflation Bond Selloff
      % Loss-43.8%-3.7%
      % Gain to Breakeven78.1%3.9%
      Time to Breakeven46 days6 days
    2015-2016 China Devaluation / Global Growth Scare
      % Loss-44.8%-12.2%
      % Gain to Breakeven81.3%13.9%
      Time to Breakeven1847 days62 days

    Compare to UP, FLYX, SRFM, JTAI

    In The Past

    Flyte Aviation's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Flyte Aviation (VJET)

    ```html

    Flyte Aviation (VJET), operating as Catheter Precision, Inc., is a medical device company specializing in the development and delivery of electrophysiology products. The company's core mission is to provide advanced technologies and solutions designed to improve the lives of patients suffering from cardiac arrhythmias. Its primary market consists of hospitals, physicians, and patients within the United States who are engaged in cardiac care.

    The company's lead product is the View into Ventricular Onset System (VIVS). This innovative, non-invasive imaging system employs 3D cardiac mapping to precisely localize the sites of origin for idiopathic ventricular arrhythmias. VIVS is utilized in patients with structurally normal hearts prior to electrophysiology (EP) procedures, assisting clinicians in targeted treatment planning.

    In addition to VIVS, Catheter Precision offers other specialized devices, including LockeT, a suture retention device, and the Amigo Remote Catheter System, a robotic arm that functions as a catheter control mechanism. These products collectively aim to enhance the efficiency and effectiveness of electrophysiology procedures, further supporting their commitment to advancing cardiac care solutions.

    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Major products of Flyte Aviation (VJET):

    • View into Ventricular Onset System (VIVO System): A non-invasive imaging system that offers 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias.
    • LockeT: A suture retention device.
    • Amigo Remote Catheter System: A robotic arm that serves as a catheter control device.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    David Jenkins, Chief Executive Officer and Executive Chairman

    Mr. Jenkins has over thirty years of experience in the medical device field, primarily with small companies. He previously served as CEO and Chairman of two other cardiac electrophysiology companies: Arrhythmia Research Technology, Inc. and EP MedSystems, Inc. Mr. Jenkins also founded Transneuronix, Inc., a company focused on implantable neurostimulators for obesity and weight loss. He began his career as a CPA with Coopers and Lybrand. He was appointed CEO of Catheter Precision on January 2, 2024, and continues as Executive Chairman of the Board.

    Margrit Thomassen, Interim Chief Financial Officer

    Ms. Thomassen was appointed interim Chief Financial Officer of Catheter Precision on January 2, 2024. She has been a full-time employee at the Catheter Precision subsidiary since 2019 and served as the company's controller since Catheter Precision's acquisition by Ra Medical in January 2023.

    AI Analysis | Feedback

    Key Risks to Flyte Aviation (symbol: VJET)

    1. Substantial Doubt About Going Concern and Continued Losses: Flyte Aviation (formerly Catheter Precision, Inc.) has faced significant challenges regarding its ability to continue as a going concern. The company has reported substantial accumulated deficits, working capital deficits, and consistent net losses and negative cash flows from its operations. For instance, in the first half of 2026, the company recorded a net loss of $5.0 million and utilized $5.7 million in operating cash. Its net loss for the full year 2025 was $17.18 million.
    2. Funding and Shareholder Dilution Risk: The company has a history of relying on securing additional equity and debt financing to fund its operations and address liquidity issues. This continuous dependence on external funding sources poses a significant risk of future shareholder dilution through new stock issuances. Additionally, a reverse stock split was implemented, a measure that, while often intended to meet exchange listing requirements and attract investors, does not guarantee sustained stock price improvement or increased trading activity.
    3. Reliance on Related Party Financing: The company has shown a pattern of heavy reliance on loans from insiders and related parties to maintain its liquidity. This extensive dependence on related party debt raises concerns about the sustainability of its funding structure and potential implications for financial independence and corporate governance.

    AI Analysis | Feedback

    1. **Disruptive Advancements in AI/Machine Learning for Cardiac Arrhythmia Diagnosis and Intervention:** Rapid developments in artificial intelligence and machine learning could lead to vastly superior, potentially non-invasive, and highly automated diagnostic tools for localizing arrhythmia origins. If AI algorithms can accurately predict or pinpoint arrhythmia sites from standard medical imaging, genetic data, or advanced ECGs, it could diminish the need for specialized 3D cardiac mapping systems like Catheter Precision's View into Ventricular Onset System. Furthermore, AI-driven catheter navigation systems, either autonomous or highly augmented, could challenge the market for current robotic catheter control devices like the Amigo Remote Catheter System by offering greater precision, efficiency, or reduced human intervention. This represents a paradigm shift in how cardiac arrhythmias are diagnosed and treated, rather than just an incremental improvement.

    2. **Emergence of Comprehensive, Integrated Electrophysiology Platforms by Major Medical Device Conglomerates:** Large, well-funded medical device companies (e.g., Abbott, Medtronic, Boston Scientific, Johnson & Johnson) are actively investing in the electrophysiology space. A clear emerging threat is the development and market introduction of highly integrated, end-to-end platforms that combine advanced non-invasive mapping, invasive 3D mapping, AI-driven real-time guidance, sophisticated robotic catheter control, and ablation capabilities into a single, cohesive, and superior system. Such integrated solutions could offer hospitals and physicians enhanced workflow efficiency, improved patient outcomes, and potentially a lower overall cost per procedure, making standalone, component-based products (like Catheter Precision's specialized mapping or robotic arm systems) less competitive or desirable. This mirrors how integrated technology platforms can displace niche product providers.

    AI Analysis | Feedback

    Addressable Markets for Catheter Precision, Inc.

    Catheter Precision, Inc. develops electrophysiology products aimed at improving the lives of patients with cardiac arrhythmias. The addressable markets for its main products are as follows:

    View into Ventricular Onset System (VO System)

    The View into Ventricular Onset System is a non-invasive imaging system for 3D cardiac mapping to localize idiopathic ventricular arrhythmias. This product falls within the cardiac mapping systems market. The global cardiac mapping market size was valued at approximately USD 4.09 billion in 2025 and is projected to reach USD 7.75 billion by 2034. In the United States, the cardiac mapping systems market was valued at approximately USD 0.81 billion in 2025. North America held 39.12% of the global cardiac mapping market in 2025. The non-contact cardiac mapping systems segment, which is highly relevant to the VO System's non-invasive nature, is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2033.

    LockeT

    LockeT is a suture retention device. This product's addressable market can be found within the broader suture anchor devices market. The global suture anchor devices market size was valued at USD 860 million in 2025 and is estimated to grow to USD 1,176.74 million by 2031, exhibiting a CAGR of 5.36% during the forecast period. North America accounted for 40.33% of the suture anchor devices market revenue in 2025.

    Amigo Remote Catheter System

    The Amigo Remote Catheter System is a robotic arm that serves as a catheter control device. This product is positioned within the robotic catheter systems or robotic catheterization system market. The global robotic catheter navigation system market size was approximately USD 1.2 billion in 2025 and is expected to reach around USD 3.4 billion by 2035, growing at a CAGR of 11.0% from 2026 to 2035. Another estimate places the global robotic catheterization system market at USD 2.8 billion in 2025, with a projected growth to USD 6.2 billion by 2034. In 2025, North America led this market with a revenue of approximately USD 0.5 billion or USD 1.24 billion. Electrophysiology represented the largest application segment within the robotic catheter navigation system market, accounting for 42.2% in 2025.

    AI Analysis | Feedback

    Flyte Aviation (VJET) is expected to drive future revenue growth over the next 2-3 years through several key initiatives, primarily stemming from its strategic repositioning to private aviation, while also maintaining its life sciences operations:

    • Expansion in Private Aviation Market: Flyte Aviation plans to expand its customer network, aircraft fleet, and geographic reach within the private aviation sector. This includes growing its fleet of Cirrus Vision Jets and connecting customers, aircraft, operators, and aviation services to modernize access to private air travel.
    • Advancements in its AI-driven Digital Booking Platform: The company intends to significantly invest in and develop its website, mobile application, and AI data analytics during the fourth quarter of 2026. This focus on technology aims to create a scalable and user-friendly booking platform, simplifying the process of accessing private air travel at competitive prices.
    • Capitalizing on Private Jet Charter Market Growth: Flyte Aviation is positioned to benefit from the projected growth in the US private jet charter market, which is estimated to increase from US$11.6 billion in 2026 to over US$16 billion by 2031. The company's strategy of offering direct-to-consumer booking with standardized pricing on select routes aims to address the complexities of this fragmented market and attract new customers.
    • Continued Revenue from Life Sciences Operations: Despite its pivot to private aviation, Flyte Aviation has stated that its life sciences operations will continue and will not be downsized. This indicates that the existing medical device products, such as the View into Ventricular Onset System, LockeT, and Amigo Remote Catheter System, will continue to contribute to the company's revenue streams.

    AI Analysis | Feedback

    null

    Peer Outperformance in Life Sciences Tools & Services

    VJET has trailed 72% of its 108 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Life Sciences Tools & Services constituents that VJET has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    100%
    of 126 industry peers · 1029900.0% return
    3Y
    56%
    of 116 industry peers · -1.9% return
    5Y
    28%
    of 108 industry peers · -88.4% return
    No Life Sciences Tools & Services peer with a comparable growth profile has beaten VJET by more than 20pp over 5Y.
    Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is VJET's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 14.6%45.3%93.9% CAH 427% · MCK 373% · COR 181%
    Health Care Facilities 24 0.4%5.6%9.6% THC 307% · NHC 280% · ENSG 140%
    Health Care Services 20 20.8%36.1%8.3% HIMS 296% · RDNT 144% · DGX 75%
    Managed Health Care 8 27.5%-7.2%3.4% OSCR 101% · HQY 40% · ELV 13%
    Health Care Equipment 50 -8.4%-2.5%-18.3% POCI 11150% · UFPT 370% · GKOS 252%
    Pharmaceuticals 62 -7.8%-6.9%-32.6% INDV 1105% · ETON 1034% · LQDA 842%
    Health Care Supplies 11 12.8%-11.8%-42.2% LNTH 301% · HAE 51% · MMSI 17%
    Life Sciences Tools & Services ← 109 -10.6%-13.2%-64.8% SNWV 2022% · NTRA 244% · MEDP 212%
    Biotechnology 362 -18.0%-26.3%-79.4% CELZ 1186% · DNTH 1091% · ELVN 1027%
    Health Care Technology 20 -31.9%-55.1%-80.7% SPOK 79% · HSTM 11% · VEEV -2%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    PACBPacific Biosciences of California0.847.5%44.4%
    PTCPTC22.140.3%10.8%
    RXORXO4.837.8%125.8%
    OPCHOption Care Health4.735.9%-2.7%
    AAOIApplied Optoelectronics10.629.3%273.4%
    STDNStandard Nuclear2.426.4%23.5%
    CIENCiena63.025.0%89.7%
    MTSIMACOM Technology Solutions26.823.4%104.7%
    HTZHertz Global0.722.6%-59.9%
    FCELFuelCell Energy1.522.2%182.5%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    LQDALiquidia2.3-63.3%-24.9%
    AVBPArriVent BioPharma0.7-48.9%-25.0%
    EMATEvolution Metals & Technologies1.2-34.0%-91.0%
    NKTRNektar Therapeutics1.3-32.6%-5.6%
    ACRSAclaris Therapeutics0.5-29.9%22.9%
    GLASGlass House Brands0.5-24.0%-41.7%
    APMDApnimed0.7-22.0%-25.4%
    SPHRSphere Entertainment3.8-21.5%10.8%
    IARTIntegra Lifesciences1.0-20.0%7.2%
    SECZSecuritize1.9-19.8%3.3%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MYPSPLAYSTUDIOS0.6780.8%602.5%
    KODKodiak Sciences5.8161.1%230.3%
    PACBPacific Biosciences of California0.8100.0%44.4%
    DNAGinkgo Bioworks0.878.6%49.3%
    MXLMaxLinear9.874.2%527.1%
    SECZSecuritize1.971.2%3.3%
    GRALGRAIL5.970.9%60.4%
    VICRVicor13.758.7%173.1%
    BALYBallys0.853.2%-15.3%
    PSPershing Square23.952.9%147.8%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CTVACorteva9.3-84.2%-79.1%
    LQDALiquidia2.3-62.3%-24.9%
    AVBPArriVent BioPharma0.7-51.2%-25.0%
    QUREuniQure1.5-48.2%-3.6%
    XNDUXanadu Quantum Technologies1.5-47.9%-56.0%
    NKTRNektar Therapeutics1.3-46.2%-5.6%
    GLASGlass House Brands0.5-41.9%-41.7%
    ACRSAclaris Therapeutics0.5-40.0%22.9%
    XENEXenon Pharmaceuticals3.6-38.8%-18.4%
    ALHCAlignment Healthcare1.7-38.2%-57.6%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    VJETUPFLYXSRFMJTAIMedian
    NameFlyte Av.Wheels U.flyExclu.Surf Air.Jet AI  
    Mkt Price0.913.771.200.931.521.20
    Mkt Cap-0.10.10.10.00.1
    Rev LTM272040411110111
    Op Inc LTM-12-225-35-75-10-35
    FCF LTM-10-446-27-68-9-27
    FCF 3Y Avg-9-360-55-74-8-55
    CFO LTM-9-24719-51-9-9
    CFO 3Y Avg-9-2305-59-8-9

    Growth & Margins

    VJETUPFLYXSRFMJTAIMedian
    NameFlyte Av.Wheels U.flyExclu.Surf Air.Jet AI  
    Rev Chg LTM219.2%-6.0%16.1%3.1%-18.1%3.1%
    Rev Chg 3Y Avg132.6%-20.9%-130.7%-17.6%56.6%
    Rev Chg Q380.7%-4.0%21.7%7.6%139.0%21.7%
    QoQ Delta Rev Chg LTM72.8%-1.0%5.2%1.9%41.9%5.2%
    Op Inc Chg LTM0.4%9.3%41.3%-112.8%15.9%9.3%
    Op Inc Chg 3Y Avg13.9%15.7%--87.9%-2.2%5.9%
    Op Mgn LTM-635.0%-31.3%-8.8%-67.3%-95.1%-67.3%
    Op Mgn 3Y Avg-1,704.6%-32.2%-19.7%-84.4%-94.1%-84.4%
    QoQ Delta Op Mgn LTM361.7%0.2%2.4%-1.4%37.1%2.4%
    CFO/Rev LTM-488.4%-34.3%4.7%-46.2%-85.3%-46.2%
    CFO/Rev 3Y Avg-1,293.8%-27.6%0.6%-53.3%-65.7%-53.3%
    FCF/Rev LTM-500.6%-61.9%-6.7%-61.6%-85.3%-61.9%
    FCF/Rev 3Y Avg-1,305.7%-44.8%-17.2%-67.4%-65.8%-65.8%

    Valuation

    VJETUPFLYXSRFMJTAIMedian
    NameFlyte Av.Wheels U.flyExclu.Surf Air.Jet AI  
    Mkt Cap-0.10.10.10.00.1
    P/S-0.20.20.80.20.2
    P/Op Inc--0.6-1.8-1.2-0.2-0.9
    P/EBIT--0.7-2.1-0.90.4-0.8
    P/E--0.5-3.0-0.80.4-0.6
    P/CFO--0.63.4-1.8-0.2-0.4
    Total Yield--241.6%-31.9%-113.2%264.2%-72.6%
    Dividend Yield-0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg--66.7%-85.2%-134.2%-102.0%-93.6%
    D/E-5.23.60.90.02.2
    Net D/E-4.63.30.7-5.32.0

    Returns

    VJETUPFLYXSRFMJTAIMedian
    NameFlyte Av.Wheels U.flyExclu.Surf Air.Jet AI  
    1M Rtn911,800.0%-13.4%4.3%38.6%21.6%21.6%
    3M Rtn911,800.0%-55.7%-34.1%1.9%-73.3%-34.1%
    6M Rtn911,800.0%-61.3%-43.4%-19.2%-80.3%-43.4%
    12M Rtn911,800.0%-91.0%-72.4%-81.9%-99.8%-81.9%
    3Y Rtn-13.2%-89.7%-88.8%-90.2%-100.0%-89.7%
    1M Excs Rtn911,798.8%-14.8%3.1%37.4%20.3%20.3%
    3M Excs Rtn911,796.0%-56.9%-32.5%-0.8%-76.3%-32.5%
    6M Excs Rtn911,783.9%-81.1%-61.0%-35.9%-98.9%-61.0%
    12M Excs Rtn911,785.5%-108.2%-88.4%-95.2%-116.6%-95.2%
    3Y Excs Rtn-86.1%-180.5%-168.4%-167.6%-184.6%-168.4%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/14/20265/18/20263/31/202611/13/20258/11/20255/14/20253/31/202511/14/20248/14/20245/6/20244/1/202412/21/2023
    Key Financials Quarterly            
    Total Revenue100000000000
    Ebitda-3-1-5-2-6-4-2-4-4-2-0-1
    Operating Income-4-2-3-3-3-3-3-3-3-3-3-3
    Net Income-3-2-5-2-5-4-6-4-4-3-1-2
    EPS-9.20-13.90-33.23-17.00-72.80-68.10-256.02-381.70-1058.30-684.002295.20-537.70
    Key Financials TTM            
    Total Revenue TTM211110000000
    Ebitda TTM-11-14-17-14-15-13-11-10-7-5-12-20
    Operating Income TTM-12-11-12-12-12-12-11-11-11-9-17-23
    Net Income TTM-13-14-17-17-19-18-17-12-9-7-71-78
    Growth Rates Quarterly            
    Total Revenue Growth380.7%202.1%59.7%135.4%128.0%74.4%16.4%-27.8%-3.1%-3.5%--
    EBITDA Growth52.4%70.1%-186.2%53.5%-58.2%-93.8%-1020.6%-152.9%-152.7%76.0%97.9%66.2%
    Operating Income Growth-39.4%32.9%6.1%-5.7%-4.5%-32.1%-17.5%-4.7%-86.1%74.8%68.0%35.6%
    Net Income Growth35.5%58.4%5.2%43.1%-21.1%-51.2%-741.3%-113.8%-167.8%96.0%91.8%59.5%
    Margins Quarterly            
    EBITDA Margin-272.6%-288.0%-2291.2%-732.3%-2752.4%-2913.3%-1278.5%-3706.2%-3966.7%-2622.0%-132.8%-1057.9%
    Operating Income Margin-388.1%-536.6%-1204.2%-1336.7%-1338.7%-2416.8%-2047.7%-2978.1%-2921.5%-3190.2%-2028.9%-2052.6%
    Net Income Margin-323.4%-389.1%-2242.0%-1037.2%-2409.9%-2828.7%-3777.2%-4291.7%-4537.6%-3262.2%-522.7%-1448.9%
    Cash & Debt            
    Total Cash200220310146
    Total Debt14124342221000
    Net Debt / (Cash)12124121-111-1-3-5
    Cash Flows Quarterly            
    FCF from Operations-3-3-2-2-2-2-3-3-2-2-2-2
    Cash Flows TTM            
    FCF from Operations TTM-9-9-8-10-10-10-9-8-7-11-21-22
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-4.2%-2.5%-3.5%-3.9%-3.1%-3.8%-4.0%-3.8%-3.7%-3.5%-3.5%-3.7%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-3.4%-3.1%-3.4%-4.0%-3.9%-4.0%-3.7%-3.6%-3.6%-3.2%-5.9%-7.8%

    Segment Financials

    Revenue by Segment
    $ Mil20252024202320222021
    Product sales100  
    Vascular   00
    Total10000


    Price Behavior

    Price Behavior
    Market Price$1.03 
    Market Cap ($ Bil)0.0 
    First Trading Date09/27/2018 
    Distance from 52W High0.0% 
       50 Days200 Days
    DMA Price$0.02$0.04
    DMA Trendindeterminateindeterminate
    Distance from DMA4,874.5%2,574.0%
     3M1YR
    Volatility0.0%4,221,333.8%
    Downside Capture�-0.00
    Upside Capture�7405.54
    Correlation (SPY)��
    VJET Betas & Captures as of 9/30/2026

     1M2M3M6M1Y3Y
    Beta������
    Up Beta������
    Down Beta������
    Up Capture0%0%0%0%0%�
    Bmk +ve Days6162766132424
    Stock +ve Days00000143
    Down Capture-0%-0%-0%-0%-0%�
    Bmk -ve Days16263760120328
    Stock -ve Days00000130

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with VJET
    VJET0.0%0.0%-47.79-
    Sector ETF (XLV)16.9%15.7%0.79-
    Equity (SPY)17.5%13.0%0.96-
    Gold (GLD)6.9%29.6%0.23-
    Commodities (DBC)46.1%20.8%1.71-
    Real Estate (VNQ)2.1%13.7%-0.10-
    Bitcoin (BTCUSD)-29.8%44.3%-0.67-

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with VJET
    VJET-100.0%726.1%1.53-
    Sector ETF (XLV)7.1%15.2%0.281.8%
    Equity (SPY)13.9%17.1%0.622.6%
    Gold (GLD)18.7%18.9%0.80-0.3%
    Commodities (DBC)10.3%19.5%0.40-0.6%
    Real Estate (VNQ)1.2%18.8%-0.040.3%
    Bitcoin (BTCUSD)16.0%52.2%0.475.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with VJET
    VJET-100.0%469.7%0.98-
    Sector ETF (XLV)10.6%16.7%0.513.1%
    Equity (SPY)15.6%17.9%0.744.4%
    Gold (GLD)11.6%16.4%0.580.5%
    Commodities (DBC)8.3%18.1%0.371.0%
    Real Estate (VNQ)4.2%20.7%0.161.9%
    Bitcoin (BTCUSD)64.1%66.2%1.044.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Earnings Returns History

    Updated 10/7/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    5/18/20260.0%0.0%0.0%
    3/31/20260.0%0.0%0.0%
    11/14/20250.0%0.0%0.0%
    8/11/2025 0.0%100.0%
    4/1/2025-19.2%-7.7%-42.3%
    11/14/202433.3%-81.7%-88.7%
    8/15/20240.0%0.0%0.0%
    5/7/202476.5%2,252.9%11,664.7%
    ...
    SUMMARY STATS   
    # Positive11109
    # Negative7910
    Median Positive0.9%0.9%0.0%
    Median Negative-4.2%-7.3%-18.5%
    Max Positive76.5%2,252.9%11,664.7%
    Max Negative-19.2%-81.7%-88.7%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    5/18/20260.0%0.0%0.0%
    3/31/20260.0%0.0%0.0%
    11/14/20250.0%0.0%0.0%
    8/11/2025 0.0%100.0%
    4/1/2025-19.2%-7.7%-42.3%
    11/14/202433.3%-81.7%-88.7%
    8/15/20240.0%0.0%0.0%
    5/7/202476.5%2,252.9%11,664.7%
    1/11/2024-2.8%-5.3%-16.8%
    6/5/2023-2.6%-7.1%-9.7%
    11/14/20226.4%4.0%-20.2%
    8/15/2022-2.5%1.7%-28.5%
    5/16/20220.9%-5.6%-4.2%
    3/23/20225.9%-5.0%0.0%
    11/15/20210.8%-10.2%-23.3%
    8/16/2021-11.5%-16.0%-12.7%
    5/11/2021-4.2%3.8%13.1%
    3/16/20218.3%-7.3%-9.9%
    11/12/2020-4.9%19.1%13.6%
    SUMMARY STATS   
    # Positive11109
    # Negative7910
    Median Positive0.9%0.9%0.0%
    Median Negative-4.2%-7.3%-18.5%
    Max Positive76.5%2,252.9%11,664.7%
    Max Negative-19.2%-81.7%-88.7%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/14/202610-Q
    03/31/202605/18/202610-Q
    12/31/202503/31/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/31/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/06/202410-Q
    12/31/202304/01/202410-K
    09/30/202312/21/202310-Q
    06/30/202312/15/202310-Q
    03/31/202306/02/202310-Q
    12/31/202203/28/202310-K
    09/30/202211/14/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/14/202610-Q
    03/31/202605/18/202610-Q
    12/31/202503/31/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/31/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/06/202410-Q
    12/31/202304/01/202410-K
    09/30/202312/21/202310-Q
    06/30/202312/15/202310-Q
    03/31/202306/02/202310-Q
    12/31/202203/28/202310-K
    09/30/202211/14/202210-Q
    06/30/202208/16/202210-Q
    03/31/202205/16/202210-Q
    12/31/202103/24/202210-K
    09/30/202111/15/202110-Q
    06/30/202108/11/202110-Q
    03/31/202105/12/202110-Q
    12/31/202003/17/202110-K
    09/30/202011/16/202010-Q
    06/30/202008/11/202010-Q
    03/31/202005/14/202010-Q
    12/31/201903/11/202010-K
    09/30/201911/29/201910-Q

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 10/6/2026